Latest Information

Below you can access the latest press releases, financial reports, corporate governance documents and more. Please note that some documents may refer to Liminal BioSciences' previous name Prometic Life Sciences Inc.

  • LMNL Corporate Presentation September

    LMNL Corporate Presentation September

    Read PDF
  • Liminal BioSciences Provides Update on Progress on BLA for Ryplazim® (plasminogen)

    Liminal BioSciences Provides Update on Progress on BLA for Ryplazim® (plasminogen)

    The FDA confirmed that the resubmission is a complete, Class 2 response and has provided a Prescription Drug User Fee Act ("PDUFA") target action date of March 5, 2021.

    Read Article
  • Liminal Biosciences to Present at The H.C. Wainwright 22nd Annual Global Investment Conference

    Liminal Biosciences to Present at The H.C. Wainwright 22nd Annual Global Investment Conference

    LMNL announced that Kenneth Galbraith, Chief Executive Officer at Liminal BioSciences is scheduled to present a company overview at The H.C. Wainwright 22nd Annual Global Investment Conference

    Read Article
  • Liminal BioSciences Announces Resubmission of Biologics License Application to U.S. Food and Drug Administration for Ryplazim® (plasminogen)

    Liminal BioSciences Announces Resubmission of Biologics License Application to U.S. Food and Drug Administration for Ryplazim® (plasminogen)

    Liminal, through its U.S. subsidiary Prometic Biotherapeutics Inc., has filed a resubmission of the Biologics License Application (BLA) for Ryplazim® (plasminogen) (Ryplazim®) with the U.S. FDA

    Read Article
  • Press Releases

    Read More
  • Annual Report 2019

    Annual Report 2019

    Read PDF
  • Quarterly Report Q3 2019

    Quarterly Report Q3 2019

    Read PDF
  • Quarterly Report 2019 Q2

    Quarterly Report 2019 Q2

    Read PDF
  • Financial Reports

    Read Now
  • Nasdaq Statement of Corporate Governance Differences

    Nasdaq Statement of Corporate Governance Differences

    Read PDF
  • ×

    Get the updates before everyone else.

    First Name
    Last Name
    * By completing and submitting this form, you understand and agree that use of Liminal BioSciences' web site is subject to Liminal BioSciences Privacy Policy
    !
    Thank you!
    Error - something went wrong!
  • Mandate of the Chair of the Board 2020

    Mandate of the Chair of the Board 2020

    Read PDF
  • LMNL Share Price

    View Now
  • CEO Position Description 2020

    CEO Position Description 2020

    Read PDF
  • Corporate Governance

    Read More
  • loading
    Loading More...